347 related articles for article (PubMed ID: 32333465)
1. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
[TBL] [Abstract][Full Text] [Related]
3. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
5. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
8. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
9. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Cherkassky L; Morello A; Villena-Vargas J; Feng Y; Dimitrov DS; Jones DR; Sadelain M; Adusumilli PS
J Clin Invest; 2016 Aug; 126(8):3130-44. PubMed ID: 27454297
[TBL] [Abstract][Full Text] [Related]
10. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Andreu-Saumell I; Rodriguez-Garcia A; Mühlgrabner V; Gimenez-Alejandre M; Marzal B; Castellsagué J; Brasó-Maristany F; Calderon H; Angelats L; Colell S; Nuding M; Soria-Castellano M; Barbao P; Prat A; Urbano-Ispizua A; Huppa JB; Guedan S
Nat Commun; 2024 Apr; 15(1):3552. PubMed ID: 38670972
[TBL] [Abstract][Full Text] [Related]
11. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
Chang ZL; Silver PA; Chen YY
J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.
Shen C; Zhang Z; Tian Y; Li F; Zhou L; Jiang W; Yang L; Zhang B; Wang L; Zhang Y
BMC Med; 2021 Nov; 19(1):283. PubMed ID: 34819055
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
[TBL] [Abstract][Full Text] [Related]
14. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
[TBL] [Abstract][Full Text] [Related]
15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
18. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
20. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]